Analysis of circulating tumor DNA from patients enrolled in the PALOMA-3 trial (fulvestrant or fulvestrant + palbociclib) identified an enrichment of Rb mutations, although this only occurred in 4.5% of the palbociclib-treated cohort [7,8]. The gene discussed is RB1; the disease is neoplasm.